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ABSTRACT
The recent explosion in the understanding of the cellular and molecular mechanisms underlying hematopoietic
stem and progenitor cell (HSPC) mobilization has facilitated development of novel therapeutic agents, targeted
at improving mobilization kinetics as well as HSPC yield. With the development of new agents comes the chal-
lenge of choosing efficient and relevant preclinical studies for the testing of the HSPC mobilization efficacy of
these agents. This article reviews the use of themouse as a convenient small animal model of HSPCmobilization
and transplantation, and outlines the range of murine assays that can be applied to assess novel HSPCmobilizing
agents. Techniques to demonstratemurineHSPCmobilization are discussed, as well as the role ofmurine assays
to confirm humanHSPCmobilization, and techniques to investigate the biologic phenotype of HSPCmobilized
by these novel agents. Technical aspects regardingmobilization regimens and control arms, and choice of exper-
imental animals are also discussed.
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esisINTRODUCTION
Transplantation using mobilized hematopoietic
stem and progenitor cells (HSPC) has revolutionized
the treatment of a wide range of hematologic and
solid tumors. For a variety of reasons, improving
the efficacy of mobilization and apheresis (HSPC col-
lection) represents an important clinical goal. First,
using current techniques, a proportion of ‘‘poor mo-
bilizer’’ patients fail to mobilize adequate HSPC
numbers to achieve the clearly defined doses required
for transplantation. Second, even in ‘‘good mobilizer’’
patients, current mobilization techniques can be
hampered by unpredictable kinetics of mobilization,
creating costly scheduling difficulties for apheresis.
Furthermore, particularly large doses of HSPC are
required for certain procedures such as double
autologous transplants and haploidentical allogeneic
transplantation. The quest for newer agents ofmobilization that are more efficacious, more predict-
able, and that may mobilize specific HSPC subtypes
with desirable characteristics (eg, phenotypes that
are particularly amenable to cell manipulation) has
produced a range of novel candidate drugs. The ap-
propriate use of animal models of HSPC mobiliza-
tion is required to test novel mobilization drugs
prior to their assessment in human clinical trials.
Herein, we describe the use of the mouse as a useful
preclinical model to assess novel drugs for HSPC mo-
bilization (Figure 1). In vitro and in vivo assay tech-
niques for the measurement of mobilized HSPC are
described, and murine assays to confirm the engraft-
ment potential of mobilized human HSPC are dis-
cussed. A practical technical section summarizes the
various mouse strains used in mobilization studies
and other practical information related to murine
transplantation assays.603
604 K. E. Herbert et al.Figure 1. Hematopoietic lineage and assays of hematopoietic stem and progenitor cells (HSPC). HSC, hematopoietic stem cell; CRU, compet-
itive repopulating unit; Hu-SCID, human cell into severe combined immune deficiency (mouse model); LTC-IC, long-term culture-initiating
cell; CAFC, cobblestone area forming cell; HPP-CFC, high proliferative potential colony-forming cell; CFU-S, colony forming unit-spleen;
CLP, common lymphoid progenitor; CMP, common myeloid progenitor; CFU-GEMM, colony-forming unit-granulocyte erythrocyte
macrophage megakaryocyte; GMP, granulocyte macrophage progenitor; MEP, megakaryocyte erythroid progenitor; CFU-GM, colony-form-
ing unit-granulocyte macrophage; CFU-M, colony-forming unit-macrophage; CFU-G-CSF, colony-forming unit-granulocyte; CFU-E, col-
ony-forming unit-erythroid; BFU-E, burst-forming unit-erythroid; CFU-Meg, colony-forming unit-megakaryocyte.Hematopoietic Stem and Progenitor Cell Biology
Hematopoietic stem and progenitor cells (HSPC)
were among the first ‘‘stem cells’’ to be identified and
exploited clinically for their ability to home to the
bone marrow and reconstitute hematopoiesis after
myeloablation. Studies in animal and human models
have identified a continuum of HSPC, ranging from
the primitive multipotent stem cell (hematopoietic
stem cell, or HSC), through to more committed pro-
genitors (Figure 1). It has been hypothesized that the
more differentiated committed progenitors engraft
quickly, providing hematopoiesis (limited to their
respective lineage) in the early days to weeks aftermyeloablation [1-5], but neither these cells nor their
progeny persist beyond this point. In contrast, the
more primitive cells are slower to engraft, but are
able to reconstitute long-term multilineage hemato-
poiesis that is detectable months to years after myeloa-
blation. Thus, successful transplantation of HSPC
requires both early- and late-repopulating cells, to re-
constitute multilineage hematopoiesis in the short and
longer term. This view of HSPC engraftment is not
without controversy, with groups as early as 1956 de-
scribing complete hematopoietic engraftment after
the transplantation of a single hematopoietic stem
cell [6]. Since then, murine models have confirmed
long-term repopulation in primary and secondary
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[7]; however, studies of human CD341 cell engraft-
ment suggest that CD341 cells can engraft as early as
day 13, whereas the more primitive CD341 CD382
subset display more delayed engraftment, starting as
late as day 36 posttransplant and continuing to in-
crease over 100 days posttransplant [8].
Hematopoietic and Stem and Progenitor Cell
mobilization
Physiologic stimulators of mobilization. Adult
HSPC normally reside in the bone marrow, but a small
proportion of HSPC have been shown to continually
exit the marrow, circulate in the peripheral blood
(PB) at low levels in normal individuals [9], and then
reenter the marrow [10]. Since the late 1970s and early
1980s, it has been shown that HSPC can be induced to
migrate out of the marrow into the PB by a variety of
stress stimuli such as strenuous physical exercise, adre-
nocorticotropic hormone [11], endotoxin [12], sulph-
ated polysaccharides, and synthetic polyanions [13],
and with active infectious mononucleosis infection
[14].
Chemotherapy as a mobilizing agent. The ob-
servation that myelosuppressive chemotherapy itself
was capable of mobilizing stem cells provided a plat-
form to explore whether this phenomenon could be ex-
ploited for human transplantation [15-18]. The precise
mechanism of chemotherapy mobilization is likely to
lie in its effects on the microenvironment where stem
cells, unlike more committed and maturing cells, are
able to withstand the myelosuppressive effects of mo-
bilizing chemotherapy. Mobilization always occurs
during the reconstitution phase of the BM that follows
myeloablation. Studies in inbred mice have shown that
the cytotoxic damage to the BM stroma and hemato-
poietic compartment induces the overexpression of
a number of stromal factors such as KIT ligand
[19,20] and CXCL12 [21,22] involved in recruiting
quiescent HSC, which are spared from the cytotoxic
effect of chemotherapy, into cell cycle. The subse-
quent proliferative and reconstitution phase leads to
expansion of myeloid cells [22], BM hypoxia [23],
and releases of granulocyte proteases [22], particularly
MMP-9, which is essential to BM survival from che-
motherapy as well as chemotherapy-induced HSC mo-
bilization [24]. Furthermore, an increase in BM
hypoxia induces vascular endothelial growth factor
(VEGF) expression and accumulation of VEGF on
BM sinuses, an event that could increase BM vascular
permeability and hematopoietic cell egress [23]. In hu-
mans, HSPC mobilization with chemotherapy alone is
unpredictable, however, resulting in only a brief period
of mobilization of HSPC within the PB, and requiring
large doses of chemotherapy, with the attendant risks
of infection and bleeding [25].G-CSF as the prototype mobilizing cytokine.
Granulocyte-colony stimulating factor (G-CSF) is
the prototype cytokine and the most widely used agent
for mobilization in clinical medicine. Its discovery as
a cytokine that could support the growth of colony-
forming units-granulocyte macrophage (CFU-GM)
in semisolid media, led to its purification and subse-
quent production to a clinically relevant scale via
recombinant technology. After its successful applica-
tion in clinical trials to support granulocyte function
in neutropenic individuals, came the recognition that
G-CSF could mobilize HSPC in humans [26,27]. In
a murine model using sex mismatched transplantation
in B6D2F1 mice, it was confirmed that G-CSF in-
duced the mobilization of transplantable HSC [28].
Transplantation of G-CSF mobilized HSPC was sub-
sequently shown to accelerate hematopoietic recovery
in human patients undergoing myeloablative trans-
plantation [29,30]. With concomitant progress in the
field of peripheral blood progenitor cell (PBPC) col-
lection and transplantation, G-CSF (with or without
chemotherapy) is now the most widely used cytokine
for HSPC mobilization in human autologous and allo-
geneic transplantation [31,32].
Since the development of G-CSF, the preclinical
testing of newer agents for mobilization has followed
a more orderly sequence. With each increment in the
understanding of the cellular and molecular mecha-
nisms of HSPC mobilization, novel agents and strate-
gies for mobilization have been proposed and tested in
a variety of animal models before being trialed in
humans.
For example, the use of the murine model has char-
acterized some of the molecular mechanisms responsi-
ble for G-CSF mobilization. A critical role for the
chemokine CXCL12 (stromal cell-derived factor-1
SDF-1) and its receptor CXCR4 was identified in
G-CSF-induced and chemotherapy-induced mobiliza-
tion, with the observation that G-CSF causes a drop in
SDF-1 concentration in the BM, and cleavage and loss
of function of its receptor (CXCR4) on immature he-
matopoietic cells within the BM. One of the mobilizing
effects of G-CSF is to increase the release of neutrophil
elastase, cathepsin G, and MMP-9 by BM neutro-
phils—proteases that degrade both SDF-1 and its re-
ceptor CXCR4 [33]. The BALB/c murine model has
been used to demonstrate that injecting an inhibitor
of elastase caused a block in G-CSF mobilization
[34]. The relevance of the proteolytic pathway to mobi-
lization in humans is revealed by the phenotype of mo-
bilized CD341 cells. Using 2 monoclonal antibodies
(mAbs) binding to 2 different regions of the CXCR
molecules, it has been shown that following G-CSF ad-
ministration, the CXCR4 molecules expressed at the
surface of mobilized CD341 cells in blood and BM
are truncated and inactive [33]. Such a truncation can
only occur following proteolytic cleavage.
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MMP inhibitors in wild-type mice abrogates or re-
duces G-CSF mobilization [34,35], it has been demon-
strated that in the C57BL/6 model, congenital absence of
neutrophil elastase and cathepsin G does not prevent
G-CSF-induced mobilization [36]. This apparently
contradictory data highlights the differences between
congenital absences versus acquired deficiency of com-
ponents of certain physiologic systems. The proteo-
lytic pathway of mobilization contains significant
redundancy, with multiple other proteases capable of
upregulation and subsequent compensation for the de-
ficiency of neutrophil elastase or cathepsin G, for ex-
ample. In knockout models, a life-long deficiency in
myeloid serine-proteases allows alternative proteases
ample time to ‘‘take over’’ the role of the missing en-
zymes. In acquired deficiency caused by the adminis-
tration of elastase inhibitors in adult wild-type mice,
abrogation of G-CSF mobilization presumably occurs
because there has been less time for compensation by
alternative proteases.
Using the BALB/c and C57BL/6 mouse models,
we have also recently reported that the transcription
of SDF-1 in the BM is strongly reduced during
G-CSF-induced mobilization; an effect independent
of neutrophil proteases [36,37]. More recently, a sub-
stantial increase in BM hypoxia has been noted in
BALB/c and 129SvJ mice mobilized with G-CSF. Ox-
ygen depletion, presumably by proliferating myeloid
progenitors, stabilizes the transcription factor HIF-
1a in BM cells, which in turn, induces VEGF expres-
sion in the BM and accumulation of VEGF protein
on BM endothelial sinuses [23]. Interestingly, mobi-
lized blood CD341 cells express high levels of HIF-
1a protein, whereas nonmobilized BM CD341 cells
do not [38]. Thus, the increase in hypoxia in mobilized
BM occurs both in mice and humans, and may be an im-
portant mechanism contributing to HSC mobilization.
Recently, the novel bicyclam AMD3100 was dem-
onstrated to mobilize HSPC by specifically and revers-
ibly blocking the binding of SDF-1 on marrow stromal
cells to its ligand CXCR4 on HSPC, in both murine
models and humans [39]. AMD3100 was initially de-
veloped as an agent against human immunodeficiency
virus (HIV) infection, as CXCR4 is an HIV corecep-
tor; however, early trials in murine models [40] and
then in healthy volunteers led to the discovery that
AMD3100 caused mobilization of HSPC in both the
mouse and humans [41]. The murine model was then
used to demonstrate mobilization of murine long-
term repopulating cells that produced hematopoietic
reconstitution in lethally irradiated primary and sec-
ondary recipient mice. The murine model was also in-
formative in identifying the molecular mechanism by
which AMD3100 mobilizes HSPC [42]. AMD3100
thus provides a good example of how murine models
enabled the transition from the discovery of a newmobilizing agent to a rational, targeted approach that
has facilitated the commencement of at least 21 phase
II clinical trials currently registered for AMD3100
(http://www.clinicaltrials.gov).
The Mouse as a Useful Small Animal Model for
Mobilization Studies
Mice share a great deal of genetic similarities with
humans, and respond in a very similar manner to most
agents that induce mobilization in humans. In the early
1960s, indirect evidence for the presence of stem cells
within the peripheral blood leukocyte fraction in mice
was obtained, through the observation that normal pe-
ripheral leukocytes from F1 hybrid mice could be
transplanted and proliferate in lethally irradiated par-
ent mice or homologous-strain animals, producing
multilineage repopulation of donor type hematopoie-
sis within these recipients [43]. The mouse became
a useful model for the study of HSPC biology because
of its small size and rapid reproductive cycle, its bio-
logic similarity with the human, and importantly, the
interspecies activity of agents such as G-CSF. Further
features in favor of the mouse as a model of HSPC bi-
ology are the variety of inbred mouse strains that are
homozygous for all autosomal genes, the extensive
congenic breeding programs that facilitate transplan-
tation experiments, and the availability of an ever in-
creasing number of mutants carrying transgenes,
homozygous-targeted gene deletion, and tissue-spe-
cific gene deletions, which enables the dissection of
molecular pathways of many biologic processes in-
cluding HSPC mobilization [40,44].
Since its early use in hematopoietic stem cell biol-
ogy, the mouse model has informed much of the sub-
sequent clinical development of novel mobilizing
agents as they came to hand. Murine models have
been used in the early development of novel agents
such as KIT ligand/stem cell factor [45,46], interleu-
kin-8/CXCL8 [47], Flt-3 ligand [48], thrombopoietin
[49], Grob/CXCL2 [50], progenipoietin [51], and
AMD3100 [52,53].
MURINE ASSAYS TO DEMONSTRATE HSPC MOBILIZATION
The hematopoietic stem and progenitor popula-
tion is a broad continuum of cells ranging from the
most primitive multipotent HSC through to lineage-
committed progenitors (reviewed in [54]). Assays of
novel agents for mobilization require quantification
of the mobilization of hematopoietic progenitors, as
well as functional assays of early- and late-repopulat-
ing cells. The ideal mobilizing agent produces mobili-
zation that is predictable (to ascertain the ideal timing
of apheresis in clinical subjects), potent (to maximize
mobilization at tolerable doses), tolerable with mini-
mal side effects, safe (producing functional, transplant-
able HSPC that successfully engraft), and cost
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the testing of all of these endpoints. Assays can be
broadly categorized according to the cell type that
they measure (committed progenitor versus immature
progenitor, versus primitive HSC), and the experi-
mental conditions utilized (in vitro versus in vivo,
and short-term versus long-term assays) (Figure 1). Fi-
nally, the biologic phenotype of mobilized cells can be
characterized by a range of in vitro assays described in
Figure 1 and Table 1, and discussed below.
Lineage-Restricted Committed Progenitors—In
Vitro Assays
Hematopoietic progenitors are capable of forming
colonies (defined as 40-50 cells or more [55]) when
grown in semisolid media with the appropriate growth
factors added. An advantage of the colony assay is its
short-term nature, providing results within\15 divi-
sions, or 12 days in the mouse. Agar or methylcellulose
based assays are popular, and provide a relatively sim-
ple and convenient mode of identification of commit-
ted progenitors, based on the morphology of colonies
formed after 12-14 days’ incubation.
The main disadvantage of short-term assays is that
they do not detect very primitive HSPC (such as
HSC). The life span of these assays is limited to ap-
proximately 3 weeks, and is unable to be replenished
once the nutrients and cytokines are consumed. This
period is insufficient to allow primitive stem cells to
produce differentiated progeny, and thus it is only
progeny of more committed progenitors that can be
assayed in this system. The most primitive murine
progenitors able to be assessed in this way include col-
ony-forming unit granulocyte-erythroid-macrophage-
megakaryocyte (CFU-GEMM), and lymphomyeloid
progenitors [56]. As an endpoint for studies of mobili-
zation, murine CFU assays report CFU-GEMM as
well as total CFU, CFU-GM, and where applicable,
burst-forming units-erythroid (BFU-E). A limitation
of CFU-GEMM scoring is that one cannot easily dem-
onstrate that these colonies arise from a single multi-
potent progenitor (ie, that they are truly clonal),
rather than being simply a mixed colony arising from
the overlap of 2 adjacent restricted progenitors.
Although inconvenient and rarely done, the ‘‘gold
standard’’ for proving clonality in mixed colonies in-
volves secondary assays in which the original colony
is replated in clonal conditions, and its capacity to pro-
duce daughter mixed colonies is confirmed. In prefer-
ence, the reporting of more mature colonies such as
CFU-GM, CFU-G, and so forth, is performed.
When used in the assessment of mobilization,
plated cells for semisolid assays can either be leuko-
cytes or purified mononuclear cells (MNC) from he-
molyzed peripheral blood, bone marrow, or spleen.
The frequency of mobilized committed progenitors
in the original specimen can be calculated andexpressed as colony-forming cells (or colonies) per
milliliter of peripheral blood, per femur or per spleen,
respectively. In murine studies of mobilization, it is of
value to report CFU from peripheral blood as well as
the spleen, as the spleen is a major site of extramedul-
lary hematopoiesis in the mouse, an interesting differ-
ence between mice and humans, the molecular basis of
which is unknown. Different mouse strains mobilize
with differing efficacy (discussed below), and to avoid
overgrowth of colonies on the plate, it is necessary to
plate less cells in so-called ‘‘good mobilizers’’ such as
BALB/c strains compared to ‘‘poor mobilizer’’ strains
such as C57BL6/J [57]. Further discussion of the tech-
nical aspects of mouse strain choice is found in the
technical section below. The advantage of colony as-
says is their relative simplicity and rapidity of results
generated. However, colony assays do not identify
true HSC, and extrapolations to HSC can sometimes
be wrong. To illustrate this point, we recently found
that some retinoids can increase the mobilization of
colony-forming cells in response to G-CSF with little
effect on HSC mobilization [57]. Conversely, Adams
et al. [58] has recently shown that pretreatment with
parathyroid hormone enhances HSC mobilization in
response to G-CSF with little effect on the mobiliza-
tion of colony-forming cells.
Immature Progenitors—In Vitro Assays
The long-term culture-initiating cell (LTC-IC) is
an in vitro liquid culture assay that uses feeder cells to
provide substrate and regulatory growth factors re-
quired for the growth of primitive hematopoietic cells.
The LTC-IC is defined as a cell that is able to produce
daughter cells that are detectable as CFU in standard
colony assays [59]. Immortalized murine bone
marrow-derived stromal cell lines (such as MS-5,
AFT024, M210B4, and S17) are popular feeder cells,
as they support both myeloid and lymphoid differenti-
ation of LTC-IC.
Similarly, the cobblestone area-forming cell
(CAFC) assay is an in vitro liquid culture assay in
which stem cells form clonal progeny that are inte-
grated in the adherent layer as groups of flattened, op-
tically dense cells (‘‘cobblestone areas’’). The CAFC
assay can be used as a limiting dilution assay for stem
cells, and it has been shown that day 8 CAFC correlate
with day 12 colony forming unit-spleen (CFU-S),
whereas day 28 CAFC correlate with the more primi-
tive pre-CFU-S [60].
A disadvantage of liquid culture assays is that un-
like colony assays, where growth in semisolid media al-
lows for separation of colonies, identification of
a discrete colony of cells as being the progeny of a sin-
gle hematopoietic progenitor is not possible, because
there is no way of discriminating cells as the actual pro-
genitors or their progeny.
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Biologic Feature of Mobilized HSPC Assay Example Interpretation of Functional Endpoint
CFU-GM CFU assays in semisolid media [61] Measure of committed progenitors within the
mobilized cellsCFU-GEMM
BFU-E
Content of primitive progenitors and
‘‘true’’ HSC
CRU assay [137] CRU per mL of mobilized peripheral
blood—a functional measure of
primitive HSC by their ability to engraft
into lethally irradiated recipients
Content of HSC with self-renewal
potential
Secondary bone marrow transplants Presence of donor-type cells in secondary
recipients indicates self-renewal of
those HSC originally transplanted into
the primary recipients
Content of early and late engrafting
cells
Non competitive transplants of
mobilized peripheral blood [57]
Time to early hematopoietic recovery after
engraftment into lethally irradiated
recipients—a measure of early-engrafting cells
within the mobilized cells
Long-term multilineage reconstitution—a measure
of primitive HSC within the mobilized cells
Day 12 CFU-S content CFU-S assay [62] Measure of immature progenitors within the
mobilized cells
SRC NOD/SCID assay [89,90] Content of SCID repopulating cells in human
mobilized PBPCs—a measure of successful
engraftment and HSC function in a xenograft
model
Surface markers for murine ‘‘HSC’’ Lineage2, c-Kit1, Sca-11 (LKS) Measure of primitive murine HSC within
mobilized cellsCD1501CD482Sca211Lineage2
c-kit1 [83]
Surface markers for murine ‘‘HSC’’ CD34neg subpopulation of LKS Measure of a subpopulation of murine LKS that
exhibit superior engraftment in transplantation
Cell cycle status 7-AAD BrDU Flow cytometric determination of cell cycle
status—an increased proportion of cells in G1 may
facilitate genetic manipulation of mobilized HSC
for therapeutic purposes
Ki-67 [105]
Cell survival/antiapoptotic features Annexin-V (79) Cell survival and antiapoptotic function correlates
with homing and engraftment of efficiency of
transplanted mobilized HSPC
Activated Caspase C [138]
Fas/CD95 [139]
Adhesion molecule expression L-Selectin [140] Relevant to the trafficking and homing of HSC to the
marrow after transplantation.LFA-1, VLA-4, VLA-5 [141]
L selectin expression on G-CSF mobilized human
CD341 cells predicts for rapid platelet recovery
posttransplant.
HSC trafficking Parabiotic assays of HSC
tracking [10]
Proportion of HSC within secondary recipients of
mobilized cells from parabionts provide
information regarding HSC trafficking at baseline
compared to that after mobilization treatment
Migration assays SDF-1a migration assay [79] Enhanced migration in vitro of CD341 cells
mobilized with G-CSF correlates with
hematopoietic recovery in humans [142]
Homing assays Carboxyfluorescein diacetate
succinimidyl (CFSE)-labeled
HSC [79]
Percentage of CFSE1 LK or LKS cells within marrow
is recorded 16 hours after transplantation.
Improved ability of labeled mobilized HSC to
home to the marrow of lethally irradiated
recipients may translate to faster engraftment.
HSC adhesion activity assays Adhesion to VCAM-1 [79] Enhanced adhesion of mobilized cells in vitro to
recombinant mouse VCAM-1 may contribute to
faster engraftment, because of improved homing
and adhesion to host marrow.
CFU-GM inidicates colony-forming unit-granulocyte macrophage; CFU-GEMM, colony-forming unit-granulocyte erythroid macrophage
megakaryocyte; BFU-E, burst-forming unit-erythroid; HSC, hematopoietic stem cells; CRU, competitive repopulating unit; CFU-S, colony
forming unit-spleen; SRC, SCID repopulating cell; NOD/SCID, nonobese diabetic-severe combined immune deficiency; PBPC, peripheral
blood progenitor cell; LKS, lineageneg c-Kit1 Sca-11; 7-AAD, 7-amino actinomycin D; BrDU, 5-bromo 2-deoxyuridine; LFA-1, lymphocyte
function associated antigen-1; VLA-4 very late antigen; SDF-1a, stromal derived factor-1; G-CSF, granulocyte-colony stimulating factor;
VCAM-1 vascular cell adhesion molecule-1.
Murine Models of HSPC Mobilization 609The LTC-IC and CAFC assays are more often
used for studies of human hematopoiesis, but are less
commonly used in murine studies of mobilization, as
they require replating with many serial dilutions, and
are time consuming (requiring .15 cell divisions or
.5 weeks). Furthermore, they are difficult to standard-
ize as different methodologies exist for each assay, and
local preferences between different laboratories can
make comparison between studies difficult [61].
Immature Progenitors—In Vivo Assays
The majority of studies investigating novel mobi-
lizing agents do utilize short-term in vitro colony as-
says for detection of committed progenitors as
described above. However, to prove and quantify (at
least indirectly) the presence and function of imma-
ture progenitors and primitive ‘‘true’’ HSCs, func-
tional in vivo transplantation and engraftment assays
are used.
Day 12 CFU-S, pre-CFU-S, and marrow repo-
pulating assays. The CFU-S assay was described in
1961 by Till and McCulloch, and remains a useful
measure of early progenitors [62,63]. The CFU-S
was 1 of the early putative stem cells, as it showed sig-
nificant proliferative potential, self-renewal character-
istics, and was able to differentiate into multiple
lineages [62,64]. These cells are capable of short-
term radioprotection, and can be seen as macroscopic
nodules of hematopoiesis on the surface of the spleens
of irradiated recipients at days 8-12 posttransplanta-
tion. CFU-S are not capable of producing sustained
hematopoiesis beyond 1 month posttransplantation,
illustrating that they function more as primitive multi-
potent progenitors than as true stem cells.
Briefly, irradiated mice are injected intravenously
with the test sample (bone marrow, eg, 5  105 cells,
spleen cells, eg, 5  105 cells or mobilized PB, eg, 1
 106 PB leukocytes) within several hours of complet-
ing lethal irradiation (typically around 10 Gy). These
recipient mice are then euthanized and their spleens
dissected at 8-12 days after transplantation. Spleens
are fixed in Bouin’s solution or Tellesniczky’s solution,
and macroscopic colonies visible on the surface of the
spleen are counted under a dissecting microscope [62]
(Figure 2). The self-renewal capacity of these CFU-S
has been confirmed by taking spleens from mice that
were irradiated and injected 11 days earlier (as above),
and injecting spleen cells into further irradiated recip-
ients. These secondary recipients were euthanized and
the number of colonies generated per CFU-S was cal-
culated, reflecting the mean self-renewal capacity of
the primary CFU-S [28,65]. It has been shown, how-
ever, that only about 5%-10% of injected CFU-S actu-
ally produce daughter colonies, and there is substantial
heterogeneity in the distribution of CFU-S per pri-
mary colony [65,66].Within the originally described CFU-S colonies
are more primitive cells that are capable of 30-day mar-
row reconstitution after irradiation, and ‘‘older,’’ more
differentiated day 12 CFU-S. These cells can be sorted
by flow cytometry on the basis of rhodamine-123 stain-
ing of mitochondrial membranes, with Rho123dull day
12 CFU-S having a greater marrow repopulating ca-
pacity than Rho123bright day 12 CFU-S [67]; however,
only a subpopulation (approximately half) of the
Rho123dull day 12 CFU-S have radioprotective ability,
indicating the capacity for long-term reconstitution
[68]. The CFU-S has since been characterized as 2
populations: day 8 CFU-S are cells that are radiopro-
tective in a dose-dependent manner, containing mainly
megakaryocyte-erythroid committed progenitors, and
largely consisting of cycling cells [69-71]; day 12 CFU-
S reflect more pluripotent HSC, and are mainly dor-
mant in the G0 stage of the cell cycle [70-72].
The value of the CFU-S assay is that it is simple to
perform, and as a short-term assay it is convenient,
providing rapid results. Its major disadvantage is that
it does not provide information about the spectrum
of mobilized cells, namely, the proportions of primi-
tive stem versus progenitor cells.
Primitive HSC—Flow Cytometric Assays
Although HSC are traditionally defined using
functional characteristics such as (1) multipotentiality
Figure 2. Murine spleen showing normal spleen (above) and macro-
scopic colony forming units-spleen (CFU-S) on the splenic surface,
at day 12 posttransplant (below). (Photo courtesy of Dr. Stewart
Fabb PhD, Barwon Biomedical Research, Geelong, Australia.)
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etic lineages), (2) long-term repopulating ability (the
ability to produce multilineage reconstitution in pri-
mary transplant recipients 4-6 months after transplan-
tation), and (3) self-renewal (the ability to produce
multilineage reconstitution in secondary transplant re-
cipients over 3 months posttransplantation), these are
all functional characteristics with certain practical lim-
itations. The main limitation is that of definition:
defining ‘‘multipotentiality’’ is hampered by the multi-
ple differing test systems used in HSC assays, with
their varying cytokine combinations and other extra-
cellular factors. Similarly, the definition of ‘‘longevity’’
is somewhat arbitrary in terms of a cutoff for the num-
ber of cell doublings that define a true primitive HSC.
Confusion also surrounds the differing types of cell
division that have been described in models of HSC
behavior; the putative dichotomy between (1) self-re-
newing and (2) differentiating divisions necessitates
the somewhat controversial assumption that these are
mutually exclusive events. Thus, the definition of
HSC using functional characteristics, although widely
used and conceptually helpful, ideally requires supple-
mentation with more definitive characteristics such as
a demonstrable cell surface phenotype using tech-
niques such as flow cytometry.
Until recently, in the mouse, there has been no
widely accepted cell surface phenotype that reliably
translates to HSC content. Traditionally, complex
combinations of markers such as Lineage2 Sca-11 c-
kit1 (LKS) have been used to purify HSC [73]. A major
limitation of phenotypic assays, such as LKS enumera-
tion without further subfractionation, is that there re-
mains substantial functional heterogeneity within
cells of this phenotype. This is illustrated by the obser-
vation that a phenotype that is homogeneous for 1 HSC
property such as longevity shows heterogeneity in other
HSC properties such as self-renewal or multipotency
[74,75]. Even with panels of up to 10-12 markers,
only 20% of ‘‘HSC’’ purified as LKS cells produced
long-term multilineage hematopoietic reconstitution
when injected into lethally irradiated recipients [76-78].
Although the CD341 count is used in humans to
indicate HSPC mobilization, this population is het-
erogeneous, containing primitive as well as more ma-
ture progenitors. In contrast, CD341 is a less useful
marker in the mouse, where there is good evidence
that murine HSC can also be CD34 negative. For ex-
ample, the CD342 subpopulation identified within
the LKS fraction in steady-statemurine BM [75,78], en-
grafts particularly efficiently in murine competitive
repopulation assays [79]. However, CD342 is less use-
ful in mobilized murine HSPC, because although
steady-state murine BM contains CD342 HSPC, G-
CSF mobilization induces phenotypic switching of
all CD342HSPC to become CD341. These cells nev-
ertheless engraft very well, and a proportion will returnto CD342 once steady state is again reached [78,80].
Further studies have demonstrated that both human
and murine CD341 cells can arise from CD342 cells,
with CD341 possibly representing an ‘‘activated’’ phe-
notype in murine HSC [81,82]. More specific markers
for the ‘‘true’’ murine HSPC phenotype are therefore
required.
Recently, microarray technology has identified
the CD2/signaling lymphocyte activation molecule
(SLAM) family of receptors as simple and highly spe-
cific markers for HSC and progenitors. In particular,
the homotypic cell surface receptor CD150, CD244
(2B4), and its ligand CD48, are each differentially ex-
pressed between hematopoietic progenitors [83]. This
simple panel of 3 markers has now been used to reliably
differentiate between true highly purified HSC
(CD1501 CD2442 CD482), multipotent hematopoi-
etic progenitors (CD1502 CD2441 CD482), and re-
stricted progenitors (CD1502 CD2441 CD481),
respectively. The use of CD412 allows distinction be-
tween CD1501 CD482 CD412 HSC, and CD1501
CD482 CD411 megakaryocytes. Whereas only 20%
of purified LKS engraft and give long-term multiline-
age reconstitution in single-cell transplantation assays,
47% of single cells purified using the CD1501CD482
Sca-11 Lineage2 c-kit1 phenotype showed engraft-
ment and long-term multilineage hematopoiesis, and
similar results were achieved using CD1501 CD482
CD412 cells, with 45% of cells purified using this
simple phenotype showing engraftment of long-term
multilineage hematopoiesis [83]. The CD1501 CD482
phenotype appears to be expressed in both steady-
state and mobilized HSC, and unlike Sca-1, which is
expressed by a restricted number of mouse strains, is
conserved among HSC of all mouse strains [83].
With the recent availability of commercial antibodies
specific for mouse CD48 and CD150, this technique
may well replace the standard LKS technique for iden-
tifying and purifying HSC and progenitors as well as
identifying these cells in immunohistologic examina-
tions of tissue sections. Once validated in culture as-
says as a true HSC, the advantage of a flow
cytometric assay for SLAM markers as HSC is clear,
as it overcomes many of the deficiencies of the LKS
marker system, and could be used as a quick, relatively
‘‘real-time’’ measure of HSPC mobilization.
Primitive HSC—In Vivo Transplantation Assays
Primary transplantation. Transplantation assays
can either be functional or qualitative, or more directly
quantitative where an attempt to calculate the fre-
quency of HSC within the transplanted tissue is
made. The abovementioned functional endpoints for
HSC (longevity, multipotentiality, and self-renewal)
can be demonstrated in transplantation assays.
Together, these endpoints provide useful criteria for
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long-term repopulation cells (LTRC), within the
transplanted material. Of these criteria, longevity is
perhaps the best reflection of ‘‘stemness,’’ as other cri-
teria such as multipotentiality are shared by the shorter
lived transplantable cells such as day 12 CFU-S [62],
pre-CFU-S [84].
For the purposes of testing a novel agent for mobi-
lization, primary transplants involve the lethal irradia-
tion of recipients followed by transplantation of
mobilized cells, and require detection of donor cell
progeny in the peripheral blood of recipients at time
points such as 5 weeks (for early donor engraftment),
and 3-4 and 6 months (for multilineage reconstitu-
tion). Primary transplantation can either be competi-
tive or noncompetitive, depending on the endpoints
intended for measurement.
Competitive repopulation assays. In the assess-
ment of new methods of HSPC mobilization it is often
useful to have a more quantitative measurement of
HSC than merely the presence or absence of donor
cells within a recipient. The competitive repopulating
unit (CRU) assay is a widely accepted as the gold stan-
dard to quantify true HSC within a transplanted unit.
This assay measures the long-term ability of a stem cell
population to repopulate the bone marrow of irradi-
ated recipients, relative to a known source of compet-
ing HSC (usually bone marrow cells from congenic
donors that are genetically identical to recipients apart
from an identifiable single locus). In these assays, do-
nor cells are therefore distinguishable from congenic
host and competitor cells, as described below.
In a competitive transplant, the test unit (which in
mobilization assays comprises mobilized peripheral
blood leukocytes or MNC) is transplanted along
with 1-2  105 competing bone marrow cells, into ir-
radiated recipients. Competing cells can be derived
from a congenic animal, and where measurement of
engraftment of the competing cells is required, cells
from an animal with an identifiable phenotype distinct
from the donor and the recipient can be used, as de-
scribed below. HSC within the test cells compete
with HSC within the competing bone marrow cells,
to occupy HSC niches and repopulate the recipients.
The role of the competing cells is 2-fold. First,
they provide short-term radioprotection of recipients
and prevent death from myeloablation during the
several weeks that it takes for test cells to engraft and
produce effector cells [85]. Second, for actual quantifi-
cation of CRU, the competing cells function to pro-
vide a fixed number of HSC against which limiting
dilutions of test cells can be transplanted. In limiting
dilution transplants, groups of recipients are trans-
planted with decreasing numbers of test cells plus
a fixed number of competing cells, and recipients are
assessed for proportion of donor-derived cells at 3-4
months posttransplant. Flow cytometry is currentlythe preferred method of determining engraftment,
and is accepted as $1% donor-derived cells in both
myeloid (Mac-11) and lymphoid (B2201) lineages, al-
though T cell and erythroid populations can also be
assessed [86]. The proportion of lineage-positive re-
cipients decreases exponentially, correlating with the
proportion of test cells to competitor cells that was
originally transplanted. Poisson statistics can be used
to determine the frequency of CRU in the transplanted
material. It is known that a single HSC from a highly
purified subset of marrow has a 100% efficient homing
ability [7], and that single HSC transplanted into le-
thally irradiated mice can repopulate the entire hema-
topoietic system, so it is thought that CRU frequency
is a good estimate of HSC frequency.
Noncompetitive transplantation assays. For as-
sessment of novel agents of mobilization, transplanta-
tion can also be performed using mobilized peripheral
blood leukocytes or MNC transplanted into lethally
irradiated congenic recipients, without competitor
cells. This technique more closely reflects the trans-
plants performed clinically in the allogeneic and autol-
ogous setting. An adequate dose of cells needs to be
transplanted to overcome the lack of competitor cells
for hematopoietic support in the peritransplant period
(see above).
Using G-CSF-mobilized murine peripheral blood,
for example, we found that a dose of 1  106 mobilized
PB leukocytes contained an adequate number of mobi-
lized HSPC, as all the mice survived the transplant,
while allowing adequate discrimination of engraftment
kinetics when compared to transplantation with PB
leukocytes mobilized with a novel mobilizing [57]. In
noncompetitive transplantation assays, the main end-
point is the time to recovery of PB neutrophils, plate-
lets, and hemoglobin, but as in the competitive model,
percentage of donor cell engraftment in the leukocyte
compartment can be measured, if donor and host cells
differ by a marker such as Hb, Y chromosome, or Ly-5
expression (see below).
Secondary transplantation. In secondary trans-
plantation assays, at 6 months posttransplant, recipi-
ents from the primary transplant are culled, and bone
marrow is transplanted into congenic irradiated sec-
ondary recipients, again choosing recipients that are
phenotypically distinguishable from the primary do-
nors. Three months postsecondary transplant the
presence of donor-derived peripheral blood or marrow
leukocytes in secondary recipients provides evidence
that these mice were indeed transplanted with HSC
from the original primary donors. Secondary trans-
plants provide further confirmation that the original
transplanted cells indeed contained long-term HSC,
and are the best indicator of stem cell self-renewal.
This proves longevity, self-renewal, and therefore
true HSC activity in the sample from the originally
mobilized mouse.
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tion assays. The advantage of transplantation assays
is that they are the best estimate of the presence of
HSC within the graft, and when competitive repopula-
tion assays are employed, they allow quantification of
these cells. The disadvantage is the time taken to col-
lect data, as true LTRC function needs to be assessed
at 6 months posttransplant, and if secondary trans-
plants are performed to confirm the presence of the
most long-lived, primitive subsets of HSC, this adds
another 3 months to the assay. Furthermore, large
numbers of mice are required, with the attendant wel-
fare and resource issues in animal housing.
Identification of donor and competitor cells
within transplant recipients. In murine models, de-
tection of donor/recipient chimerism posttransplant is
facilitated by careful choice of donor and recipient
phenotype. For example, C57BL/6 mice that express
hemoglobin (Hb)bs can be transplanted with cells
from single-locus congenic C57BL/6 Hbbd mice,
and erythroid engraftment can then be measured 3
months after marrow transplant by gel hemoglobin
electrophoresis, using a scanning densitometer [87].
The disadvantage of this method is that it only mea-
sures erythroid reconstitution, whereas other methods
(see below) of donor cell detection measure peripheral
blood leukocytes in multiple lineages. Electrophoresis
is also time consuming, and has recently been largely
replaced by flow cytometric techniques.
Other more widely used techniques for detection
of donor cells within transplant recipients include the
use of donor cells, which differ from recipient cells
by either a sex marker (eg, male cells transplanted
into female recipients, detected by a marker for the
Y chromosome such as SRY [88]) or a congenic
marker, for example, Ly-5/CD45 polymorphism be-
tween C57BL/6 mice, which express CD45.2, and
B6.SJL-PtprcaPep3/BoyJ, which are genetically identi-
cal apart from the expression of CD45.1 on the latter.
Ly5/CD45 is expressed on all hematopoietic cells ex-
cept erythrocytes, and polymorphism between
CD45.1 and CD45.2 provides a quick and convenient
method for detecting donor cells within leukocytes of
recipients using flow cytometric techniques. Further-
more, in competitive transplants, if identification of
the competitor contribution to recipient leukocytes is
desired, the competitor cells can be sourced from
a CD45.1/CD45.2 (Ly5.11/Ly5.21) heterozygote
(the result of a F1 intercross between C57BL/6 and
B6.SJL-PtprcaPep3/BoyJ).
NONOBESE DIABETIC (NOD)/SCID MURINE
REPOPULATING CELL (SRC) ASSAYS TO CONFIRM HUMAN
HSPC MOBILIZATION
The ability to quantify HSC within a given sample
by competitive repopulation in lethally irradiated re-cipients is obviously not possible in the human setting.
The SRC model is the best available, although not ideal
as a relatively low proportion of human HSCs engraft
in NOD/SCID mice. Unlike in the mouse, there are
no in vivo models to quantify human HSC within a graft
or volume of mobilized blood or marrow, other than
engraftment after transplantation. Once mobilization
with a novel agent has been assessed in an animal
model, a reliable preclinical model is required to assess
the engraftment potential of human HSPC. Early-
phase clinical trials of a novel mobilizing agent can pro-
vide mobilized human CD341 cells, which, prior to
their application in human transplantation, can be
tested for their ability to engraft into animal models.
Proof of engraftment in this model provides an initial
indication that the novel agent was indeed able to mo-
bilize functional HSC when used in humans.
Intuitively, large animal models such as sheep or
nonhuman primates would seem an ideal choice be-
cause of their homology to humans in both size and
life span; however, there are limitations that are diffi-
cult to overcome. To overcome the immunologic bar-
rier of xenogeneic transplantation of human cells into
immunocompetent animals, transplantation must oc-
cur in utero, when the fetus is immunologically toler-
ant. Although this has been achieved (reviewed in [61]),
the immune deficient murine model is attractive both
from a cost- and space-saving perspective.
In the immune-deficient murine model, mouse
strains with genetic defects leading to profound and
permanent immune deficiency have been developed,
which are able to tolerate human xenografts. It has
been determined that optimal engraftment into the
host animal of multilineage human hematopoiesis in-
cluding T cells requires abolition of host NK cell activ-
ity, such as in the NOD/SCID b2-microglobulin-null
mouse [89]. The NOD-SCIDgc2
/2 model was re-
cently developed by deleting the gene encoding the
common gc chain common to the receptors of the in-
terleukin-2 family cytokines (IL2Rgc or CD132). The
complete absence of T and NK cell activity, and re-
duced dendritic cell function in these mice led to im-
proved multilineage reconstitution of human
hematopoiesis, including human T cells, and human
antibody production [90].
In these models, human cells (ie, mobilized HSPC),
usually in the form of MNC isolated by standard sepa-
ration on Ficoll-Hypaque and enriched for CD341
cells using immunomagnetic separation, are prepared
and injected into irradiated recipients. Engraftment
and detection of human hematopoiesis in NOD/
SCID models is relatively simple—flow cytometric de-
tection of cells using antihuman antibodies, and colony
assays selective for the growth of human progenitors
in semisolid media are commonly employed [89].
Engraftment is measured 1 month after transplantation
by the presence of human DNA within murine marrow,
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mosome probes [91,92]. Limiting dilution techniques
can be applied in this model to determine the frequency
of engrafting cells within a mobilized graft, using Pois-
son statistics [93].
There are practical issues surrounding NOD/
SCID transplants, particularly related to the poor tol-
erance of these mice of radiation, necessitating lower
radiation doses administered prior to transplantation
(3.5-4 Gy), specialized housing, and posttransplant
support with supplements of human cytokines if
\500 human cells are injected [94]. A further disad-
vantage of SCID models is that the endpoints in these
assays vary in their specificity. The definition of posi-
tivity for human DNA in the NOD/SCID marrow
ranges from 0.1%-1% human DNA in the marrow,
or a marrow content of at least 1% human CD451
cells. Neither of these criteria is entirely specific for
‘‘true’’ multipotent human HSC, as both methods
will identify some cells that probably do not repopulate
both lymphoid and myeloid lineages [61].
More specific measurement of truly multipotent
transplantable cells of human origin within the NOD/
SCID recipients can be achieved by demonstrating
clonal multilineage cell growth in culture that arises
from transplanted human cells. NOD/SCID BM is
collected 4 months after transplantation with human
CD341 cells. These cells are sorted such that single
recipient CD341 CD192 CD382 cells are plated for
culture on murine stromal cells. Clones containing
.500 cells 2-3 weeks later can be subcultured in condi-
tions favoring B, NK, and myeloid cell and thymocyte
development. Detection of differentiated cells of all lin-
eages arising from the single recipient CD341 CD192
CD382 BM cell proves the multipotency of those cells
within the original graft of human CD341 cells [95].
Others have postulated that these complicated
methods can be replaced simply by analyzing NOD/
SCID recipients for human cells at a later time point
posttransplantation, for example, longer than 6 months
posttransplant, when it can be assumed that the total
level of human engraftment is accurately reflected by
lymphomyeloid repopulating cells in the recipient [96].
Validation of the NOD/SCID murine model of
engraftment as a useful and clinically significant end-
point for mobilization of HSC is evident in the case
of AMD3100, where initial promising results in
NOD/SCID engraftment of human HSPC mobilized
using this agent [42,53] later translated into brisk and
stable engraftment when this agent was used in human
autologous and allogeneic transplantation [97].
ASSAYS TO DEMONSTRATE THE BIOLOGIC PHENOTYPE
OF MOBILIZED CELLS
It may be of interest to researchers to examine not
only for the presence of mobilized HSPC, but forcertain biologic features that may indicate HSPC func-
tion and predict for clinical usefulness in transplanta-
tion or genetic manipulation. Biologic features of
interest in mobilized HSPC may include the number
of phenotypically defined HSPC (LKS or subsets),
cell cycle status, apoptosis, adhesion molecule expres-
sion, static adhesion, in vitro migration assays, and
homing to recipient marrow of cells mobilized with
the investigational agent. Table 1 outlines a selection
of phenotypic assays that may be employed to build
a phenotypic profile of mobilized cells that may predict
their usefulness in clinical medicine.
The cell-cycling status of mobilized HSPC may be
of relevance to the emerging field of genetic manipula-
tion of HSC for therapeutic purposes. Unlike their BM
counterparts, most mobilized HSPC are not cycling
but quiescent in the G0/G1 phase of the cell cycle
[98-101]. For example, a recent study in nonhuman
primates of PBSC mobilized using AMD3100 demon-
strated that mobilized cells were more likely to be
in the G1 phase of the cell cycle, and to express
CXCR4 and VLA-4, compared with G-CSF mobi-
lized cells [102]. This may be of particular importance,
as it has been shown that retroviral or lentiviral gene-
transduction of primitive hematopoietic cells is aided
by the use of target cells that are in the G1 phase of
the cell cycle [103,104]. Cell cycle status can be as-
sessed directly by flow cytometry using the incorpora-
tion of fluorescent DNA intercalating dyes such as
DAPI, Hoescht 33342, 7-amino actinomycin D (7-
AAD), DA, or the Ki-67 nuclear antigen [105]. The
advantage of cell cycle status measurement is that it
provides an indication of whether cells mobilized by
a particular novel agent are likely to be amenable to
cell manipulation, for example, with viral-mediated
genetic manipulation, which opens up a wide range
of therapeutic possibilities for mobilized HSPC. Alter-
natively, retroviral transduction efficiency can be mea-
sured directly, and compared with (for example)
steady-state BM cells, or HSPC mobilized using con-
ventional methods [106].
Improved tracking and homing efficiency of mobi-
lized cells may be of benefit if it results in enhanced en-
graftment and hematopoietic recovery after clinical
transplantation. Studies of HSC homing and traffick-
ing can employ the use of the parabiotic model, first
developed by Bunster and Meyer in 1933 [107].
Briefly, congenic mice that are distinguishable, for ex-
ample, by Ly5.1/5.2 phenotype (as described above),
are subjected to surgery in which the circulations of
the 2 mice are anastomosed, creating a joint circula-
tion. Parabiotic pairs can be treated with a mobilizing
agent such as G-CSF or an investigational agent, and
studied at later time points after varying periods of
parabiosis [10]. The distribution of HPSC coming
from each congenic mouse of the parabiotic pair can
then be analyzed in all possible tissues, particularly
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garding HSC trafficking through marrow, the spleen,
and blood at baseline and after exposure to mobilizing
agents [10]. Tracking assays in the analysis of HSPC
mobilized using a novel agent for mobilization are
potentially useful in predicting whether the mobi-
lized HSPC are of a phenotype with particularly effi-
cient engraftment—a highly desirable feature in
transplantation.
POTENTIAL PITFALLS IN MURINE MODELS OF
MOBILIZATION
Although the murine model has many advantages
in the assessment of novel agents of mobilization, there
are potential gaps in its ability to fully predict whether
a putative agent will be clinically useful. Some novel
agents may mobilize HSPC efficiently in the mouse
and simply fail to translate into the human system.
Other agents may mobilize efficiently in all species
but carry toxicities that are less apparent in mice, and
more in larger animals, such as nonhuman primates.
Occasional toxicities ultimately only become apparent
during Phase I clinical trials in human subjects. Stem
cell factor (SCF) is an example where its activity alone,
plus synergy with G-CSF in mobilizing HSPC was
well demonstrated in mice [45,46]. A potentially sig-
nificant side effect of mast cell degranulation was
noted, however, after SCF injection in mice [108]
and dramatic expansion of mast cell populations was
seen in primates injected with SCF [109]. Later studies
showed SCF-induced mast cell degranulation in the
human lung [110] and skin [111] mast cells, producing
concerns that similar degranulation and anaphylaxis
might occur in humans. Mobilization synergy between
SCF and G-CSF has, however, since been well de-
scribed in humans, interestingly with acceptable toler-
ability [112-114].
TECHNICAL CONSIDERATIONS
Methods of Murine Mobilization
Cyclophosphamide (CY)-induced and
50fluorouracil (5-FU)-induced mobilization. CY
is a fast-acting alkylating agent, and can be adminis-
tered intraperitoneally as a single dose of 200 mg/kg,
which causes transient myelosuppression at days 2-4
in the mouse. By 6-8 days post-CY, the peripheral
blood leukocyte count rises, overshooting the baseline
value to reach approximately 1.6 times normal. At this
time point, elevated numbers of CFU-S can be ob-
served in the peripheral blood of CY-treated mice.
Transplantation of peripheral blood HSPC from
CY-treated mice into lethally irradiated recipients
shows that the level of CFU-S peaks in the peripheral
blood at 6-8 days post-CY mobilization, reaching 9.3
times normal. By day 10 post-CY injection, CFU con-
tent in the blood declines to baseline levels [115].5-FU is a nucleotide analog also frequently used to
elicit mobilization in the mouse. Doses of 250 mg/kg
injected intravenously in mice cause myelosuppression
within 3 days, followed by mobilization of HSPC,
which rehome to the BM by day 10 postinjection [24].
G-CSF mobilization. G-CSF mobilization is fre-
quently used as the control treatment in experiments
to assess novel mobilization regimens. Daily or twice
daily injections of clinical grade recombinant human
G-CSF produce a rise in CFU-S in the peripheral
blood by day 4 of injections [116]. Because of the lower
affinity of human G-CSF for the murine receptor and
the faster clearance of human proteins in mice, the mo-
bilizing dose of G-CSF for mobilization was originally
determined as 250 mg/kg twice daily in early experi-
ments, on the basis of preliminary work that demon-
strated that this regimen was on the dose-response
plateau for pharmacodynamic effects on peripheral
blood neutrophil and HSPC. More recent work, how-
ever, has shown that doses of 125 mg/kg twice daily or
even 125 mg/kg once daily [117] achieves the same de-
gree of mobilization. G-CSF can either be diluted in
sterile saline or 5% dextrose [115], or PBS with 0.1%
bovine serum albumin [28]. The recent availability of
the pegylated form of G-CSF provides a promising
and more convenient alternative to daily or twice daily
injections of G-CSF. A single injection of 25 mg PEG-
G-CSF produces a bimodal peripheral blood leukocy-
tosis, peaking at 20  106 cells/L within hours of
injection, and again at day 3 postinjection. Peripheral
blood CFU-GM and CAFC rise to peak at approxi-
mately day 3 postinjection, with later peaks possible
in the poor mobilizer mouse strains such as C57L
[118].
AMD3100 mobilization. The novel bicyclam
AMD3100 is a reversible inhibitor of the CXCR4/
SDF-1 interaction that mobilizes HSPC within hours
of injection [41,42,119,120]. Significant mobilization
of CFU-GM, BFU-E, and CFU-GEMM is noted af-
ter a single subcutaneous injection of AMD3100 at
murine doses of 5 mg/kg. Mobilization is maximal at
1 hour after injection. Mobilization synergy between
AMD3100 and G-CSF has been demonstrated across
a variety of different mouse strains, and has since
been shown in humans [42]. Synergy has been de-
scribed in mice treated with G-CSF at 250 mg/kg twice
daily for 2 days prior to AMD3100 injection, and also
for 4 days prior to AMD3100 injection [42].
Anticoagulation of Harvested PBPC
Transplantation assays of mobilized cells either
employ the transplantation of whole peripheral blood
leukocytes or purified MNC. Many researchers have
found that harvesting of PBPC for whole blood leuko-
cyte transplantation necessarily requires anticoagula-
tion of the sample immediately after collection. This
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specimen that can interfere with cell counts, producing
potentially lethal embolism if injected into recipients.
Mobilized peripheral blood should be collected into
tubes containing anticoagulant, such as EDTA or
lithium heparin, and should be processed immediately
by dilution into sterile PBS with additional unfractio-
nated heparin added [57,115]. To further reduce the
risk of formation of microclots when mobilized
peripheral blood is injected into lethally irradiated
recipients, individual recipient mice can also be in-
jected with 50 U of unfractionated heparin subcutane-
ously, approximately 15 to 30 minutes prior to
whole blood harvest (Graham Molineux, personal
communication).
Mouse Strains and HSPC Mobilization
In humans, there is a wide interindividual variation
in the efficiency of HSPC mobilization in response to
usual stimuli; there are also wide variations in the mo-
bilization responses of different experimental mouse
strains. It is known that the commonly used experi-
mental mouse strains have disparate sizes of their mar-
row stem and progenitor pools, as well as cellular
proliferation rates. Some strains with large stem cell
pools, for example, the AKR and DBA/2 strains, mobi-
lize large numbers of CFU into the peripheral blood
after G-CSF treatment [121]. At the other extreme,
the C3H/He strain, which has a small stem cell pool,
mobilizes poorly in response to pegylated G-CSF
[122].
However, the size of the stem cell pool does not
entirely predict for mobilization efficacy. Although
C57BL/6 and BALB/c have similar intermediate-sized
primitive HSPC pools (as measured by day 28 and day
38 CAFC [121]), BALB/c mobilize far more progeni-
tors into the peripheral blood for a given dose of
G-CSF, compared to C57BL/6 (Table 2). Similarly,
Roberts et al. [123] found that mouse strains mobilized
with differing efficacy in the following order: DBA .
129Sv.BALB/c5 SJL.C57Bl/6. Although not a di-
rect measure of HSC, Roberts et al. [123] also found
that baseline total body, peripheral blood, bone mar-
row, and spleen CFU-GM were similar between
C57BL/6 and BALB/c, suggesting that differences in
mobilization efficacy between mouse strains may not
be related to total body progenitor numbers, but rather
to strain-specific differences in distribution of progen-
itors in response to G-CSF. Table 2 illustrates the
loose association between stem cell pool size and mo-
bilization efficacy in response to G-CSF.
Genetic determinants of stem cell pool size are yet to
be fully elucidated; however, de Haan and Van Zant
[121] have mapped a locus to chromosome 18 that
shows high concordance with the distribution pattern
of mouse strain differences in mobilization efficacy.Interestingly, this putative locus shows synteny with
human chromosome 5q, and deletions of this region
in humans are associated with various hematologic
malignancies including 1 of the myelodysplastic syn-
dromes and a subset of acute myelogenous leukemias
(AMLs). Prior studies estimating stem cell pool size
in mouse strains have been limited by the use of surro-
gate markers such as CAFC, and progenitor assays,
rather than testing for ‘‘true’’ HSC numbers. Until re-
cently, measurement of ‘‘true’’ HSC in various mouse
strains was limited because of the practical difficulties
associated with the gold standard test for HSC, that is,
long-term competitive repopulation. With the advent
of more reliable HSC markers such as the Lin-
CD1501CD482CD412, which is likely to be applica-
ble to all mouse strains [83], it will be possible to
address this question in a more specific and accurate
manner.
Genetic determinants of mobilization efficacy are
also yet to be clarified, but Hasegawa et al. [124,125]
have implicated loci on murine chromosomes 2 and
11, and suggestive linkages on chromosomes 4 and
14, in the control of mobilization in both a poor mobi-
lizer strain (C57BL/6) and a good mobilizer mouse
strain (DBA/2). Hasegawa et al. [124] have proposed
various candidate genes on these chromosomes that
may influence mobilization efficacy such as histidine
decarboxylase (on chromosome 2), the integrin sub-
unit a4 (on chromosome 4), and transcobalamin II
(on chromosome 11). De Haan also reported that the
levels of mobilization in response to PEG-G-CSF in



















Mobilization efficacy in various mouse strains: *as measured by PB
CFU-GM after injection with pegylated G-CSF (118); †as mea-
sured by PB CFU-GM after G-CSF injection of 200 mg for 5 days
(123); and ‡as measured by PB CFU formation after G-CSF for 2
days followed by AMD3100 5 mg/kg single injection (41). Stem
cell pool size in various mouse strains: §as measured by day 28
and day 35 CAFC (121); ¶as measured by baseline total body,
PB, BM, and spleen CFU-GM [123].
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bilizer AKR strains showed significant genetic linkage
with the Aat locus in chromosome 12 containing a clus-
ter of genes encoding serine protease inhibitors (ser-
pins) of the a1-antitrypsin and a1-antichymotrypsin
family [92]. It was later found that these serpins are in-
deed expressed in the BM, control the proteolytic ac-
tivity of neutrophil proteases in this tissue, and that
their transcription is strongly downregulated during
mobilization, enabling the accumulation of proteolyt-
ically active proteases [125a].
The relative contribution to mobilization outcome
of (1) variation in size of stem cell pool versus (2) the
inherent mobilization efficacy is as yet unclear, butmay have implications as to the appropriate test for
a novel agent, depending on its mode of action. Al-
though inbred strains with larger stem cell pool sizes
mobilize better, it is yet to be determined whether
this simply is because they had more HSC to begin
with, or because of strain-specific differences in gran-
ulocyte production, protease production, SDF-1/
CXCR4 kinetics, or other contributors to the mobili-
zation pathway including pharmacogenomics.
Recent data in humans highlights the difficulty in
finding predictors of poor mobilizers. Although bio-
logic parameters such as steady-state peripheral blood
CD341 levels of $2.65  106/L predicted successful
mobilization with high accuracy, low steady-stateFigure 3. Possible schema for investigation of a novel agent for HSPC mobilization.
Murine Models of HSPC Mobilization 617CD341 levels did not predict for mobilization failure
[126]. Exposure to large amounts of chemotherapy
or radiation, or particular chemotherapeutic agents
such as melphalan [127] and fludarabine [128] predict
for poor mobilization presumably because of reduc-
tion in stem cell pool size; however, other factors
may well be at play, as some patients exposed to these
agents still mobilize HSPC adequately. There is grow-
ing interest in genetic polymorphisms to explain these
interindividual (or interstrain in the case of the mouse)
differences in the biologic effects of various drugs,
which is the subject of pharmacogenomic studies
[129]. This growing field of research may ultimately
increase the understanding of the biology behind mo-
bilization efficacy and mobilization failure.
Selection of the appropriate mouse strain for inves-
tigation of novel agents for mobilization therefore re-
quires consideration of mobilization efficacy in the
particular strain, and ideally involves demonstration
of mobilization of at least 2 different strains of differ-
ing intrinsic mobilization efficacy, to exclude the pos-
sibility of strain-specific phenomena.
Mouse Sex and HSPC Mobilization
Apart from appropriate strain selection, there is ev-
idence that mobilization efficacy in mice (and possibly
humans) may vary with sex, and particularly with the
hormonal cycle in female individuals. Although female
sex did not emerge as a significant factor affecting mo-
bilization in a series of 400 healthy allogeneic human
donors in a multivariate analysis [130], sex had a minor
influence in univariate analysis, with females mobiliz-
ing less PBSC; an effect not explained by differences
in body weight or surface area. Although possible sex
differences in the pharmacokinetics of G-CSF have
been hypothesized in rats [131], it is notable that
many of the human studies finding a poorer mobiliza-
tion efficacy in females have been performed using
healthy donors, including young, often premenopausal
women in whom as-yet undefined effects of the estrous
cycle could be playing a role [132]. Female mice
housed together tend to synchronize their estrous cy-
cle as a result of being in a social group, or if exposed
to male mouse urine, because of the olfactory effects
of environmental pheromones [133-136]. For this
reason, male mice may be the better choice for
mobilization experiments, to exclude the possibility
of confounding effects of estrous cycle on mobilization
results.
For transplantation experiments, selection of
mouse strains is partly dictated by the intended
method of detection of donor cells within recipients.
Sex-mismatched transplantations using PCR for de-
tection of Y chromosome naturally decrease the limita-
tions on choice of strain (male donors into female
recipients being the usual pattern). Regardless ofchoice of strain and method of chimerism detection,
the use of female mice as transplant recipient is often
associated with fewer problems with aggression and
fighting, which is preferable for mice housed together
for these long-term experiments.
CONCLUSION
There is an increasing demand for improved
HSPC mobilization strategies to overcome the prob-
lem of human ‘‘poor mobilizers,’’ and to increase the
efficiency HSPC mobilization where increased
HSPC numbers are required for transplantation pro-
cedures such as tandem and haploidentical allogeneic
transplants. Clinical mobilization is no longer re-
stricted to the use of G-CSF with or without chemo-
therapy, as the increasing understanding of the
mechanisms of forced HSPC egress from the marrow
leads to the development of novel agents for mobiliza-
tion. The murine model provides an excellent model of
mobilization for the assessment of these novel agents,
with a suggested schema outlined in Figure 3. Choice
of the appropriate assay for HSPC mobilization facil-
itates the accumulation of a body of data, which can be
informative not only on the presence of HSPC within
the peripheral blood of the animal, but also the func-
tionality of the HSPC, and allows for some prediction
of how the agent will perform in the human setting.
The limitations of each assay means that the best inter-
pretation of the utility of a novel agent for HSPC mo-
bilization is gained when the assays are surveyed as
a whole.
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